Sign In
Buy ASH
$57.58
-0.430 (-0.741%)
At Close: Jun 02, 2026
Ashland sets date for first-quarter fiscal 2026 earnings release and conference call webcast
05:01pm, Tuesday, 20'th Jan 2026
WILMINGTON, Del., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its first-quarter fiscal 2026 earnings release at approximately 5 p.m.
HARBOR CAPITAL ADVISORS, INC. Buys 4,850 Shares of Ashland Inc (ASH)
01:52pm, Tuesday, 20'th Jan 2026
Summary HARBOR CAPITAL ADVISORS, INC. raised its stake in Ashland Inc (ASH) by 10.06%, purchasing 4,850 shares to own 53,083 shares valued at about $3,
Ashland Inc. (NYSE:ASH) Announces $0.42 Quarterly Dividend
07:30am, Tuesday, 20'th Jan 2026
Ashland Inc. (NYSE: ASH - Get Free Report) declared a quarterly dividend on Monday, January 19th. Investors of record on Sunday, March 1st will be paid a dividend of 0.415 per share by the basic mater
Ashland board authorizes quarterly dividend
05:01pm, Monday, 19'th Jan 2026
WILMINGTON, Del., Jan. 19, 2026 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.415 cents per share on the company's common stock.
Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data
08:30am, Wednesday, 24'th Dec 2025
Lyell Immunopharma (LYEL) has surged 191% YTD, driven by strong momentum and promising CAR T-cell therapy pipeline candidates LYL314 and LYL273. LYL314 achieved a 93% overall response and 76% complete
Pre-Market Stock Futures: Futures are trading higher on Monday as we head into the final trading weeks of 2025. All of the major indices were hit hard on Friday as investors began a big rotation last
NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that an independent peer
Over 20 Studies of InnoCare's Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
08:22pm, Tuesday, 09'th Dec 2025
BEIJING, Dec. 09, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today
ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company en
ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company en
ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company en
Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
04:30pm, Monday, 08'th Dec 2025
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASH--Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025.
SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance
Autolus presented preliminary data from the Phase 1 CARLYSLE trial in patients with severe refractory systemic lupus erythematosus (srSLE) at ASH 2025.
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 8, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company developing CID-103, a potentially best-in-cl
